https://pmc.ncbi.nlm.nih.gov/articles/PMC7207225/
ELUCIDATION OF PELAREOREP PHARMACODYNAMICS IN A PHASE I TRIAL IN PATIENTS WITH KRAS MUTATED...
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target....